12
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6159 |
LY-2584702 free base
|
S6 Kinase; mTOR | MAPK; PI3K/Akt/mTOR signaling |
LY-2584702 free base 是一种选择性的 ATP 竞争性 p70S6K 抑制剂,IC50为 4 nM,对S6K1的IC50为 2 nM,用于研究癌症治疗的试验。 | |||
T1746 |
LY-2584702 tosylate salt
LY2584702 tosylate |
S6 Kinase | MAPK; PI3K/Akt/mTOR signaling |
LY-2584702 tosylate salt 是一种选择性的 ATP 竞争性 p70S6K 抑制剂,IC50为 4 nM,对S6K1的IC50为 2 nM,用于研究癌症治疗的试验。 | |||
T11928 |
M2698
MSC2363318A |
Akt; mTOR | Cytoskeletal Signaling; PI3K/Akt/mTOR signaling |
M2698 (MSC2363318A) 是 p70S6K、Akt1 和 Akt3 的抑制剂,IC50 为 1 nM。 M2698 显示出抗癌活性。 | |||
T6303L |
CCT128930 hydrochloride
CCT128930 hydrochloride(885499-61-6 Free base) |
Apoptosis; Akt; PKA; mTOR; Autophagy | Apoptosis; Autophagy; Cytoskeletal Signaling; PI3K/Akt/mTOR signaling; Tyrosine Kinase/Adaptors |
CCT128930 hydrochloride (CCT128930 hydrochloride) 是一种选择性 AKT 抑制剂,具有抗肿瘤活性。它通过靶向 AKT 的 Met282 (PKA-AKT 嵌合体的 Met173),对 PKA 激酶具有 28 倍的选择性,对 p70S6K 具有 20 倍的选择性。 | |||
T6304 |
AT7867
|
Akt; PKA; S6 Kinase | Cytoskeletal Signaling; MAPK; PI3K/Akt/mTOR signaling; Tyrosine Kinase/Adaptors |
AT7867 是 ATP 竞争性的Akt1/Akt2/Akt3和p70S6K/PKA 抑制剂,IC50分别为 32、17、47 和 85、20 nM。 | |||
T2482 |
AT13148
|
ROCK; SGK; Akt; PKA; S6 Kinase | Cell Cycle/Checkpoint; Cytoskeletal Signaling; MAPK; Metabolism; PI3K/Akt/mTOR signaling; Stem Cells; Tyrosine Kinase/Adaptors |
AT13148 是一种 ATP 竞争性 AGC 激酶口服抑制剂,能够抑制 Akt1/Akt2/Akt3、p70S6K、PKA 和 ROCKI/ROCKII 的活性,IC50值分别为 38/402/50、8、3 和 6 nM/4 nM。 | |||
T1920 |
Capivasertib
AZD5363 |
Akt; PKA; mTOR; Autophagy | Autophagy; Cytoskeletal Signaling; PI3K/Akt/mTOR signaling; Tyrosine Kinase/Adaptors |
Capivasertib (AZD5363) 是一种广谱的 AKT 抑制剂,对 Akt1、Akt2 和 Akt3 均有抑制活性 (IC50=3/7/7 nM),具有口服活性。Capivasertib 具有抗肿瘤活性,可以用于治疗乳腺癌。 | |||
T11900 |
LY-2584702 hydrochloride
|
S6 Kinase | MAPK; PI3K/Akt/mTOR signaling |
Ly-2584702 hydrochloride is a p70S6K selective ATP competitive inhibitor with IC50 of 4 nM.In the S6K1 enzyme assay, the IC50 of LY-2584702 was 2 nM. | |||
T39733 |
Hu7691 free base
|
Akt | Cytoskeletal Signaling; PI3K/Akt/mTOR signaling |
Hu7691 free base 是一种具有口服活性、高效性和选择性的 Akt 抑制剂,对多种神经母细胞瘤细胞系的抗增殖和神经发生作用。Hu7691 free base 抑制 Akt1、Akt2 和 Akt3 ,诱导神经母细胞瘤细胞分化。 | |||
T10275 |
AKT-IN-3
|
Akt | Cytoskeletal Signaling; PI3K/Akt/mTOR signaling |
AKT-IN-3 is a potent, orally active low hERG blocking Akt inhibitor (IC50: 1.4 nM, 1.2 nM, and 1.7 nM for Akt1, Akt2, and Akt3). AKT-IN-3 (compound E22) also exhibits good inhibitory activity against other AGC family kinases, such as PKA, PKC, ROCK1, RSK1 | |||
T10274 |
AKT-IN-2
|
Akt | Cytoskeletal Signaling; PI3K/Akt/mTOR signaling |
AKT-IN-2 is a selective, and orally bioavailable AKT inhibitor (IC50: 5 nM for AKT1). | |||
T39899 |
Hu7691
|
Akt | Cytoskeletal Signaling; PI3K/Akt/mTOR signaling |
Hu7691 是一种具有口服活性、选择性和高效性的 Akt 抑制剂,抑制 Akt1、Akt2 和 Akt3,抑制神经母细胞瘤细胞增殖,诱导神经母细胞瘤细胞的分化。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-04540 |
S6K1/RPS6KB1 Protein, Human, Recombinant (GST)
p70(S6K)-alpha,PS6K,p70-... |
Human | Baculovirus Insect Cells |
PS6K, also known as RPS6KB1, is a serine/threonine-protein kinase. It belongs to the RSK (ribosomal s6 kinase) family. Members of this family function in signal transduction. PS6K is an isoform of p70 ribosomal S6 kinase (S6K). S6K can be activated by mitogenic stimuli such as growth factors, insulin and cytokines. It phosphorylates the ribosomal protein S6. PS6K also phosphorylates other proteins such as elF4B, eEF2K and SKAR. It is a crucial effector of mTOR(rapamycin) signaling. PS6K is disso... |